利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.054 秒)

    Biccyclic compounds as GATA modulators
    6.
    发明授权
    Biccyclic compounds as GATA modulators 失效
    双环化合物作为GATA调节剂

    公开(公告)号：US07989463B2

    公开(公告)日：2011-08-02

    申请号：US12553694

    申请日：2009-09-03

    申请人： Dibyendu De ,  Ish Kumar Khanna ,  Sivaram Pillarisetti

    发明人： Dibyendu De ,  Ish Kumar Khanna ,  Sivaram Pillarisetti

    IPC分类号： A61K31/517

    CPC分类号： C07D239/70 ,  C07D401/04 ,  C07D403/04 ,  C07D413/04

    摘要： Novel bicyclic compounds of the formula (I), stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of forming novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided: wherein R1, R2, m, and n are defined herein.

    摘要翻译： 提供式（I）的新型双环化合物，新型双环化合物的立体异构体和/或药学上可接受的盐，和/或新型双环化合物的立体异构体的药学上可接受的盐。 另外，提供了形成新型双环化合物的新型双环化合物，立体异构体和/或药学上可接受的盐的方法，和/或新型双环化合物的立体异构体的药学上可接受的盐：其中R1，R2，m和n为 本文定义。

    Purinylalkyl benzamide derivatives
    9.
    发明授权
    Purinylalkyl benzamide derivatives 失效
    丙基烷基苯甲酰胺衍生物

    公开(公告)号：US5861403A

    公开(公告)日：1999-01-19

    申请号：US725307

    申请日：1996-10-02

    申请人： Ish Kumar Khanna ,  Richard Mathias Weier

    发明人： Ish Kumar Khanna ,  Richard Mathias Weier

    IPC分类号： C07D473/00 ,  A61K31/52 ,  C07D473/30 ,  C07D473/40

    CPC分类号： C07D473/00

    摘要： The present invention relates to compounds of the formula ##STR1## wherein HET is ##STR2## m is an integer from 1 to 4; R.sup.1 and R.sup.2 are independently selected from the group consisting of linear or branched alkyl of 1 to 6 carbon atoms; and cycloalkyl or cycloalkylalkyl having 3 to 7 ring carbon atoms, the ring carbon atoms optionally substituted with one or more alkyl groups having 1 to about 4 carbon atoms each;X is a substituent selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkylthio, and alkylthioalkyl, wherein each of said alkyl moieties has from 1 to about 6 carbon atoms; andY and Z are independently selected from the group consisting of hydrogen, alkoxy of about 1 to 6 carbon atoms and halogen;and pharmaceutical compositions containing a therapeutically effective amount of the compounds in combination with a pharmaceutically acceptable carrier and a method for treating diseases mediated by platelet activating factor.

    摘要翻译： 本发明涉及下式的化合物，其中HET是（i）图像（ii）和（iii）m是1至4的整数; R 1和R 2独立地选自具有1至6个碳原子的直链或支链烷基; 和环碳原子数为3〜7的环烷基或环烷基烷基，环碳原子任选被一个或多个具有1至约4个碳原子的烷基取代; X是选自氢，卤素，烷基，烷氧基，烷氧基烷基，氨基烷基，烷基氨基烷基，二烷基氨基烷基，烷硫基和烷硫基烷基的取代基，其中每个所述烷基部分具有1至约6个碳原子; Y和Z独立地选自氢，约1至6个碳原子的烷氧基和卤素; 以及含有治疗有效量的化合物与药学上可接受的载体组合的药物组合物和用于治疗由血小板活化因子介导的疾病的方法。